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Background: Arsenic in drinking water is a public health issue affecting hundreds of millions of people worldwide.
This review summarizes 30 years of epidemiological studies on arsenic exposure in drinking water and the risk of
bladder or kidney cancer, quantifying these risks using a meta-analytical framework.
Methods: Forty studies met the selection criteria. Seventeen provided point estimates of arsenic concentrations in
drinking water and were used in a meta-analysis of bladder cancer incidence (7 studies) and mortality (10 studies)
and kidney cancer mortality (2 studies). Risk estimates for incidence and mortality were analyzed separately using
Generalized Linear Models. Predicted risks for bladder cancer incidence were estimated at 10, 50 and 150 μg/L
arsenic in drinking water. Bootstrap randomizations were used to assess robustness of effect size.
Results: Twenty-eight studies observed an association between arsenic in drinking water and bladder cancer. Ten
studies showed an association with kidney cancer, although of lower magnitude than that for bladder cancer. The
meta-analyses showed the predicted risks for bladder cancer incidence were 2.7 [1.2–4.1]; 4.2 [2.1–6.3] and; 5.8
[2.9–8.7] for drinking water arsenic levels of 10, 50, and 150 μg/L, respectively. Bootstrapped randomizations
confirmed this increased risk, but, lowering the effect size to 1.4 [0.35–4.0], 2.3 [0.59–6.4], and 3.1 [0.80–8.9]. The
latter suggests that with exposures to 50 μg/L, there was an 83% probability for elevated incidence of bladder
cancer; and a 74% probability for elevated mortality. For both bladder and kidney cancers, mortality rates at
150 ug/L were about 30% greater than those at 10 μg/L.
Conclusion: Arsenic in drinking water is associated with an increased risk of bladder and kidney cancers, although
at lower levels (<150 μg/L), there is uncertainty due to the increased likelihood of exposure misclassification at the
lower end of the exposure curve. Meta-analyses suggest exposure to 10 μg/L of arsenic in drinking water may
double the risk of bladder cancer, or at the very least, increase it by about 40%. With the large number of people
exposed to these arsenic concentrations worldwide the public health consequences of arsenic in drinking water
are substantial.
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Arsenic (As) is a naturally occurring toxic metalloid
prevalent in the earth’s crust [1]. It enters drinking-water
sources in a dissolved state primarily resulting from the
weathering of rocks [2]. Human exposure to As involve
multiple pathways [3-9], with drinking water being the
primary route of exposure for the majority of highly ex-
posed populations [4,9,10]. West Bengal, Bangladesh and
Taiwan are the most affected regions worldwide [4,11-14].
In these areas, As concentration as high as 4,700 μg/L
have been reported in drinking water, and levels in excess
of 300 μg/L are common. High levels of As in drinking
water have also been reported elsewhere, such as North
and South America, Central and Eastern Europe as well as
Australia [4,11,15-22].
The contamination of drinking water by As has be-
come an ongoing public health issue affecting hundreds
of millions of people worldwide. A growing body of
evidence supporting a wide range of acute and chronic
effects on health, including cancer [5,20-72], has led the
World Health Organization (WHO) to lower the advis-
ory limit for concentration of As in drinking water from
25 μg/L to a provisional guideline limit of 10 μg/L [10].
However, many developing countries continue to endorse
an effective upper limit of 50 μg/L [4].
The International Agency for Research on Cancer
(IARC) has classified inorganic As in drinking water as a
Group 1 carcinogen [73]. Suggested mechanisms of ac-
tion for As carcinogenesis include oxidative damage,
epigenetic effects and interference with DNA repair,
mechanisms which have been specifically implicated in
the development of As-related urinary tract cancers which
are the focus of this review [74-81]. Urinary tract cancers
comprise primarily cancers of the urinary bladder and
kidney, the former being the ninth most common cause of
cancer worldwide [82]. Most studies generally report on
bladder or kidney cancer, although some of the studies in-
cluded in this review and meta-analysis reported histolo-
gies, mostly urothelial/transitional cell and renal cell
carcinomas. Tobacco smoking and most notably, the in-
gestion of high levels of inorganic As are two important
risk factors for bladder and kidney cancers [83-86].
To date, epidemiological studies of populations ex-
posed to high levels of inorganic As have shown strong
associations and dose–response relationships between
As in drinking water and bladder cancer and; potential as-
sociations with kidney cancer [23]. Typically, these studies
report on areas of extreme exposure where levels of As in
drinking water range from 150 to over 1000 ug/L. The ex-
tent to which health effects may develop remain uncertain
at lower levels of exposure (< 150 μg/L), with many stud-
ies failing to demonstrate the risk that might be expected
by extrapolation from findings related to high levels of
exposure [5].This paper reviews findings from epidemiological stud-
ies published over the past 30 years, including a number
of recent publications focusing on low-levels exposure
and bladder and kidney cancer outcomes [60,63,67,87].
It also quantifies the risk of urinary tract cancers due to
exposure to As in drinking water, combining risk esti-
mates from published epidemiological data. As such, this
work complements the recent systematic review of IARC
which reports on carcinogenicity following exposure to
As [23].
Most studies reporting on urinary cancers risk and As
exposure tend to focus on specific levels of exposure. By
combining exposure levels from multiple studies, the
review profiles a more complete and continuous range
of As exposure from which to better assess and predict
cancer risks associated with varying levels of exposure.
This meta-analytical approach is especially relevant to
shed light on dose–response relationship, especially at
the lower end of the curve where there has been the
most uncertainty and where a large number of people
may be at risk.Methodology
Review process
Searches of the Medline (PubMed) and Embase databases
were conducted to identify studies reporting on exposure
to As in drinking water and urinary tract cancer outcomes
and published prior to January 2013. The search condi-
tions are presented in Table 1. Searches were also under-
taken using Google Scholar and the WHO and the IARC
publications [3,23]. Studies were selected based on the
selection criteria listed in Table 1. Information abstracted
from reviewed articles is shown in Tables 2, 3, 4, 5, 6.
When the distribution of As in drinking water was de-
tailed in another publication, that information was also
retrieved. Where available, the adjusted relative risks
estimates and associated 95% confidence intervals were
selected.Data analysis
Epidemiologic data from studies which explicitly pro-
vided point estimates of As levels in drinking water were
used in a meta-analysis to examine the association be-
tween cancer outcomes and As exposure over a broader
and more continuous range of As than previously avail-
able (Tables 2, 3, 4, 5, 6, studies with an asterisk). Studies
using cumulative exposure to As in drinking water, years
of artesian well water consumption or As toenail/urine
concentrations were not included in the meta-analyses.
Risk estimates from studies reporting on bladder cancer
mortality (10 studies) were analysed separately from those
reporting on incidence (7 studies). With regards to kidney
cancer, only risk estimates for mortality could be analysed
Table 1 Search conditions and criteria for study selection
Search conditions Study selection
((arsenic) AND ("bladder cancer*" OR "kidney cancer*" OR "urinary tract cancer*" OR
"upper urinary tract cancer*" OR "urinary tract cancer*" OR "urologic neoplasm*" OR
"cancer*, urinary tract" OR "kidney neoplasm*" OR "carcinoma, renal cell*" OR "urinary
bladder neoplasm*" OR "urinary tract disease*" OR "kidney tumour*" OR "bladder
tumour*" OR "bladder tumor*"OR "kidney tumor*" OR renal cell* carcinoma” OR
"bladder neoplasms") AND ("water" OR "drinking water" OR "water supply" OR
"toenail" OR "urine" OR "well water") †
1. Arsenic in drinking water, toenail or urine, as exposure
of primary interest.
2. Urinary tract cancers incidence and mortality as primary
outcome.
3. Original study that published the data.
4. Relative risk estimates, measures of variability (i.e.,
confidence intervals) documented.
5. Epidemiological study designs, including ecological,
case-control or cohort study.
6. English language publications.
†The wildcard (*) was used to identify any other characters.
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kidney cancer incidence.
Combined risk estimates from studies reporting on
standardized mortality ratios (SMR) were modeled using
a least squares linear regression model for the logged
SMRs; studies reporting mortality rates or relative risk
(RR – incidence data only) were analyzed with a General-
ized Linear Model having a Gamma-distributed response
and a log link function, a combination well suited to
analyses with highly variable risk estimates [97]. Risk
estimates were modeled as a function of logged As and a
categorical variable with a level for each study. The latter
accounted for possible variations in baseline risk between
studies due to differing methodological designs, study
quality, populations, etc., and was assumed to be a fixed
effect (herein, referred to as Model I, see Boreinsteign
et al. [98]). The robustness/sensitivity of the predicted risk
estimates obtained with the fixed effects As-risk models
was assessed with bootstrap randomizations (10,000 per-
mutations) which estimated the effect size at 10, 50 and
150 μg/L of As in drinking water (herein, referred to as
Model II, see Efron and Tibshirani [99]). A random effects
assumption was also examined; however, the small num-
ber of studies entering each model precluded a stable esti-
mation of the variance components. Meta-analyses (Model
I and II) modeling SMR and RR were only performed for
bladder cancer due to the limited number of studies
reporting on kidney cancer. Inference of risk at 10, 50 and
150 μg/L of As in drinking water and based on Model I,
was only possible for bladder cancer incidence for which a
reliable referent population and sufficient number of stud-
ies were available. Finally, the effect of sex and smoking on
cancer risk was examined; however, analyses could not be
completed due to insufficient degrees of freedom. Six of
the 7 studies included in the meta-analysis of the RR
had been adjusted for tobacco smoking in the original
publication – an important risk factor in the develop-
ment of urinary tract cancers and a possible effect
modifier in the cancer-As relationship [51,86,100]. Only
one of the 8 studies included in the analyses of the SMRadjusted for smoking [34], as these were generally
ecological studies with no individual-level information
on smoking. A list of covariates assesses in the original
publication appear on Tables 3, 4, 6. Analyses were
performed using R 2.13.0 [101].
Results
Study characteristics
The search resulted in the review of 249 abstracts, with
50 studies being retained for full text review (Figure 1).
In total, forty studies met the inclusion criteria (princi-
pally, As in drinking water, toenail or urine as exposure
measure and urinary tract cancer as outcome of interest)
as listed in Table 1. Of these, 20 were ecological, 11 were
case–control and 9 were cohort epidemiological studies.
Thirty-seven of the 40 studies reported on bladder can-
cer outcomes and of these, 13 also reported on kidney
cancer outcomes. One study focused exclusively on kid-
ney cancer mortality [61]. Seventeen studies qualified for
inclusion in the meta-analysis, 7 reporting on bladder
cancer incidence and 10 on bladder cancer mortality.
Two studies also reported on kidney cancer mortality,
which was analysed independently from bladder cancer
outcomes. Metrics of exposure included: As in well drink-
ing water (median, average or range), cumulative As ex-
posure, years of artesian well water consumption and As
in toenails or urine. When measured in drinking water,
exposure covered a broad spectrum of As concentrations,
ranging from the study-specific detection limit to over
3,500 μg/L and with most study areas showing levels
exceeding the WHO advisory limit (Figure 2). Adverse
cancer outcomes were reported over the entire range of
concentrations, although more consistently in regions
where exposure levels were high, typically above 150 ug/L
(Figure 2).
Quality assessment
The quality of the studies was variable. For examples, all
ecological studies assessed As exposure using group level
(median or average) or ecologic measurements of drinking








Chen et al. 19853 [24] 84 villages from 4
neighbouring townships
on SW coast, Taiwan
Mortality 1968-82 Median arsenic content of artesian well and (range):
780 μg˙•L−1 (350–1,140); in shallow well: 40 (0.0–300).
Period of samples collection not reported.
ICD 188 SMRmale 167 11.0 (9.33–12.7)
SMRfemale 165 20.1 (17.0–23.2)
[Comparison of mortality rate in Blackfoot
disease-endemic areas (BFD) with those of the
general population.]




Mortality 1973-86 Arsenic well water concentration (μg˙•L−1). Period of
samples collection not reported.
ICD9 188
General population ASMRmale
< 300 – 3.1
300-590 – 15.7
≥ 600 – 37.8
– 89.1
General population ASMRfemale
< 300 – 1.4
300-590 – 16.7
≥ 600 – 35.1
[Comparison of mortality rate in BFD with those of
the general population.]
– 91.5




Mortality 1973-86 Arsenic well water concentration (μg˙•L−1) based on
well water samples collected between 1964–66.
ICD8 188
< 300 ASMRmale 23 22.6
300–590 36 61.0
≥ 600 26 92.7
< 300 ASMRfemale 30 25.6
300–590 36 57.0






including 4 from BFD
endemic area
Mortality 1972-83 Average arsenic levels in water samples of all 314
geographical units. 73.9% had < 5% of wells with
> 50 μg˙•L−1 ; 14.7% had 5-14%; 11.5% had ≥ 15%.
Well water samples collected between 1974–76.
ICD 188
All precincts & townships ASMRmale – 3.9 (0.5)
ASMRfemale – 4.2 (0.5)
Southwestern townships ASMRmale – 3.7 (0.7)















Table 2 Summary results from ecological studies reporting on arsenic exposure and the risk of bladder cancer (Continued)
Chiang et al. 19937
[29] (Table Two)
BFD endemic area in
Taiwan and 2
neighbouring areas
Incidence 1981-85 Exposure not evaluated, but based on Chen et al.
1985, the median arsenic content of artesian well in
this area was 780 μg˙•L−1 (350 – 1,140); that of
shallow well was 40 μg˙•L−1 (0.0 – 300). Period of





[Comparison of incidence rate in BFD with those of













26 counties in Cordoba,
Argentina
Mortality 1986-91 Arsenic drinking water concentration ranging from
100 to 2,000 μg˙•L−1.
ICD9 188
*Hopenhayn-Rich
et al. 1998 [36] (Tables
Three, Four)
Low 113 0.80 (0.66–0.96)
Medium SMRmale 116 1.28 (1.05–1.53)
High (178 μg˙•L−1 on average) 131 2.14 (1.78–2.53)
Low 39 1.21 (0.85–1.64)
Medium SMRfemale 29 1.39 (0.93–1.99)
High (178 μg˙•L−1 on average) 27 1.82 (1.19–2.64)
[Arsenic measurements from a variety of sources,
including official reports of water analyses from the
1930, 2 scientific sampling studies and a water survey.]
Guo et al. 19979 [37]
(Table Two)
243 townships in Taiwan Incidence 1980-87 Arsenic well water concentration ranging from < 50
to > 640 μg˙•L-1.
ICD 188 RDmale – 0.57 (0.07)
Estimate presented measured at > 640 μg˙•L-1. RDfemale – 0.33 (0.04)
[Arsenic measurements from a National survey of
83,656 wells in 243 townships, collected mostly
between 1974–76.]
Rivara et al.1997 [38]
(Table Four)
Chile Mortality 1950-92 Annual average arsenic concentration in drinking
water for Antofagasta (Region II of Chile) ranging
between 40 to 860 μg˙•L-1. Data from historical
records from 1950–1992.
ICD 188 RR – 10.2 (8.6–12.2)
[Comparison of mortality rate in Region II (exposed















Table 2 Summary results from ecological studies reporting on arsenic exposure and the risk of bladder cancer (Continued)
Smith et al. 1998 [39] Chile Mortality 1989-93 Region II of Northern Chile with population
weighted average arsenic concentration in drinking
water up to 569 μg˙•L−1 compared with the rest of
Chile; exposure generally < 10 μg˙•L−1.
N/A SMRmale 93 6.0 (4.8–7.4)
SMRfemale 64 8.2 (6.3–10.5)
[Arsenic measurements from 1950–94.]
Hinwood et al. 1999
[88] (Table Two)
22 areas in Victoria,
Australia
Incidence 1982-91 Median water arsenic concentration ranging 13
μg˙•L−1 to 1,077 μg˙•L−1.
ICD 188,
189.1-189.3
SIR 303 0.94 (0.84–1.06)
[Selected areas were those where samples with soil
and/or water arsenic concentration were generally
in excess of 10 μg˙•L-1. Period for samples collection
is not available.]
*Tsai et al. 1999 [41]
(Tables Two, Three)
4 townships from BFD
endemic area in SW
coast, Taiwan
Mortality 1971-94 Median arsenic content of artesian well: 780 μg˙•L−1
(range: 350–1,140). Period of samples collection not
reported. Authors state that artesian wells were no
longer used by the mid-1970s.
ICD9 188 SMRlocal-male 312 8.92 (7.96–9.96)
SMRnational-male 312 10.5 (9.37–11.7)
[Comparison of mortality in BFD endemic area with
that of a local reference population (Chiayi-Tainan
county) and that of Taiwan as a whole.]
SMRlocal-female 295 14.1 (12.51–15.8)
SMRnational-female 295 17.8 (5.70–19.8)
*Lamm et al. 200410
[89] (Table One)
133 counties in 26 states,
USA
Mortality 1950-79 Arsenic groundwater water concentration (μg˙•L−1).
Period of samples collection not reported.
N/A Counties
3.0–3.9 SMRwhite_male 53 0.95 (0.89–1.01)
4.0–4.9 SMRwhite_male 22 0.95 (0.88–1.02)
5.0–7.4 SMRwhite_male 28 0.97 (0.85–1.12)
7.5–9.9 SMRwhite_male 14 0.89 (0.75–1.06)
10.0–19.9 SMRwhite_male 11 0.90 (0.78–1.04)
20.0–49.9 SMRwhite_male 3 0.80 (0.54–1.17)
50.0–59.9 SMRwhite_male 2 0.73 (0.41–1.27)
[Median arsenic concentration ranged between 3–
60 (μg˙•L−1), with 65% of the counties and 82% of
the population in the range of 3–5 (μg˙•L−1).]
Marshall et al. 2007
[50] (Table Three)
Chile Mortality 1950-2000 Northern Chile (Region II) with population weighted
average arsenic concentration in drinking water up
to 569 μg˙•L−1 vs Region V which is otherwise
similar to Region II but not exposed to arsenic.
Between 1958–1970, arsenic concentration in water
supply of Antofagasta and nearby Mejillones
(Region II) averaged 870 μg˙•L−1 and declined in
the 1970s when water treatment plants were
installed.
ICD 188
RRmale-1971–73 9 1.71 (0.80–3.69)
RRmale-1974–75 9 5.95 (2.22–16.0)
RRmale-1977–79 17 2.10 (1.19–3.72)
RRmale-1980–82 35 5.04 (3.13–8.10)
RRmale-1983–85 41 5.77 (3.66–9.09)
RRmale-1986–88 47 6.10 (3.97–9.39)















Table 2 Summary results from ecological studies reporting on arsenic exposure and the risk of bladder cancer (Continued)
RRmale-1992–94 62 4.95 (3.47–7.06)
RRmale-1995–97 56 4.43 (3.07–6.38)
RRmale-1998–2000 58 4.27 (2.98–6.11)
RRfemale-1971–73 7 3.45 (1.34–8.91)
RRfemale-1974–75 4 3.09 (0.90–10.6)
RRfemale-1977–79 10 5.39 (2.24–13.0)
RRfemale-1980–82 22 9.10 (4.59–18.1)
RRfemale-1983–85 22 8.41 (4.30–16.4)
RRfemale-1986–88 37 7.28 (4.44–12.0)
RRfemale-1989–91 35 6.61 (4.02–10.9)
RRfemale-1992–94 42 13.8 (7.74–24.5)
RRfemale-1995–97 44 7.60 (4.78–12.1)
RRfemale-1998–2000 50 9.16 (5.76–14.5)




Mortality 1979-97 Population weighted median arsenic concentration
in water of 7.58 μg˙•L−1. Data from 9,251 well water
samples collected between 1983–2002.
ICD9 188 SMRmale 348 0.94 (0.82–1.08)
SMRfemale 171 0.98 (0.80–1.19)
*†Pou et al. 201112
[63] (Table Two)
26 counties in province
of Cordoba, Argentina
Mortality 1986-2006 Arsenic drinking water concentration ( μg˙•L−1).
Period of samples collection not reported.
ICD10 C67
Low (0–40) SMRmale – 3.14 (2.9–3.4)
Medium (40–320) – 4.0 (3.6–4.5)
High (320–1,800) – 4.7 (4.1–5.4)
Low (0–40) SMRfemale – 1.0 (reference)
Medium (40–320) – 0.94 (0.84–1.1)
High (320–1,800) [Arsenic measurements from
many surveys, one dating 50 years prior to study
publication but with arsenic levels showing high
degree of consistency with a more recent survey
with no exact date detailed.]
– 1.2 (1.04–1.4)




Mortality 1979-2003 Median arsenic content of artesian well: 780 μg˙•L-1
(range: 350–1,140). [Period of samples collection not
reported. Artesian wells in the region were dug in
the 1920s but no longer used by mid-1970s. Results
show a comparison of mortality in BFD endemic
area with that of Taiwan.]
ICD9 188 SMR 785 5.3 (4.9–5.6)
†Aballay et al. 201211
[62] (Table Two)
123 districts in province
of Cordoba, Argentina
Incidence 2004 Arsenic water samples from 3 aquifers: (1) Rjojan
plain (concentration ranged 0–40 μg˙•L−1 - 23 wells),
(2) Pampean mountains (0–320 μg˙•L−1- 114 wells)
and (3) Chaco-Pampean plain (0–1,800 μg˙•L−1 - 301
wells). In 80 wells, arsenic was undetected.
N/A RRmale – 13.8 (6.80–28.0)















Table 2 Summary results from ecological studies reporting on arsenic exposure and the risk of bladder cancer (Continued)
†Fernández et al.
2012 [55]
Antofagasta, Chile Mortality 1983-2009 Arsenic drinking water concentration ranging 800–
900 μg˙•L−1. [Arsenic levels based on the last 60
years and obtained from the local tap water
company in Antofagasta. Results compares
mortality rate in Antofagasta with the rest of Chile.]
ICD10 C67 RRmale – 5.3 (4.8–5.8)
RRfemale – 7.8 (7.0–8.7)
RRboth_sex – 6.1 (5.7–6.6)
*Study included in meta-analyses.
†Recent study not included in the International Agency for Research on Cancer 2012 review (Monograph 100C [23]).
1 All ecological studies assessed arsenic exposure at the group-level.
2ICD = International Classification for Disease for cancer site abstracted which included, bladder and urothelial/transitional cell carcinoma of the bladder or kidney. Transitional cell carcinoma of the renal pelvis often
share the same etiology as bladder cancer, and as such, have been treated as bladder within the meta-analyses as recommended by IARC [23]. N/A = not available.
3SMR, standardized mortality ratio.
4Age-standardized mortality rates per 100,000 using the 1976 world population as standard population and based on 899,811 person-years.
5All age-standardized mortality rates shown are significant at p < 0.001 based on trend test.
6 Regression coefficient showing an increase in age-adjusted mortality per 100,000 persons-years for every 0.1 ppm increase in arsenic level, adjusting for indices of industrialization and urbanization. Standard errors
are in brackets. Bladder cancer was significantly correlated with average arsenic level in water.
7Incidence rate per 100,000, adjusted for age.
8County is the unit of analysis.
9RD, rate difference (per 100,000 person-years) for one unit increase in the predictor and associated standard error for exposure > 640 μg˙•L−1(SE). Results shown for transitional-cell carcinoma.
10Average annual age-adjusted (to U.S. 1970 standard population) death rates per 100,000 abstracted at the state level for each decade were used as standard rates to calculate county-specific SMRs.
11Incidence rate ratio estimates with arsenic as continuous.
12Used lung cancer mortality rates as surrogate to smoking - may result in an overestimation of risk where smoking has declined; an underestimation of risk where smoking has increased; and an over-adjusted model



















































Year of artesian water
consumption:







0 (referent) 17 1.0 – – – –
1 – 20 19 1.27 – – – –
20 – 40 10 1.68 – – – –
≥ 40 23 4.10 – – – –
[Median arsenic content of
artesian wells and (range): 780
μg˙•L−1 (350 – 1,140). History of
artesian well water noted.]
Bates et al. 1995
[31] (Table
Three)
Utah, USA Incidence N/A Individual level
‘measured’
Cumulative dose index of
arsenic (mg):
117:266 age, sex, smoking,
exposure to chlorinated
surface water, history of
bladder infection,
education, urbanization of
the place of longest
lifetime residence, and





< 19 (referent) 14 1.0 10 1.0 4 1.0



















ranged 0.5 - 160 μg˙•L and av-
eraged 5 μg˙•L. Data on arsenic
levels in public drinking water
supplies were collected in
1978–79. Results are based on
the 71 cases who had lived in
study towns for at least half of
their lives. Residential history

















61:275 age, sex, smoking
< 0.1 23 1.0 8 1.0 8 1.0





























Table 3 Summary results from case–control studies reporting on arsenic exposure and the risk of bladder cancer (Continued)
[Only subjects with drilled
wells; median total arsenic
concentration of 0.1 μg˙•L ;
max.concentration of 64 μg˙•L
and 1% exceeding 10 μg˙•L.
Water sampled from wells used
by the study population at
least for 1967–80. Exposure in
the 3rd-9th calendar year prior
to cancer diagnosis. Residential
history and drinking water con-
sumption used in exposure
assessment.]












49:224 age, sex, BMI, cumulative
arsenic exposure,
cigarette smoking, hair
dye usage, education0 – 2 30 1.0 – – – –
> 2 – 12 4 0.6
(−1.1–3.0)
– – – –
> 12 10 1.86
(0.2–5.10)
– – – –
[Arsenic concentration in
artesian well water from survey
of 83,656 wells between 1974–
76. Questionnaires used to
determine village in which
subjects lived 30 years ago.
Residential history and duration
and; source of drinking water












Cumulative exposure to arsenic
in water (mg˙•L−1•year):
181:328 OR for all participants
adjusted for age, gender,
occupation, smoking
history (<1 pack per day




< 6.4 153 1.0 23 1.0 130 1.0













7,000 samples from community
and domestic wells. Results for
a 40 years lagged exposure;
88.4% of cases and 91.8% of
controls being exposed to
arsenic levels ranging from 0 to
19 μg˙•L, respectively.
Residential history, source of




























114:114 mate con bombilla
consumption, education,
and home tap-water con-
sumption in all groups;
and adjusted for the
highest daily number of
cigarettes subjects re-
ported ever having
smoked in the smoker
group




















of 5 years of highest exposure
during the period 6–40 years
before interview. On average,
cases and controls had 25.7
and 25.6 years of well-water
consumption, respectively; also
approximately 50% of all well
years were derived from proxy-
well data. Results shown for












383:641 age, sex, smoking status
(ever/never)































0 – 14 2.17
(0.92–5.11)
[Levels of arsenic in toenails
reflect exposures occurring
between 9–15 months prior to
sample collection. On average
cases and controls had 16.5
and 17.2 years exposure to
their water system. Results































280:293 age, toenail collection
date, intervention group,
number of cigarettes per
day, and number of
years smoking
< 0.105 – – – – 136 1.0
0.105–0.160 – – – – 73 1.10
(0.73–1.64)
0.161–0.259 – – – – 37 0.93
(0.56–1.54)
0.260–0.399 – – – – 20 1.38
(0.68–2.80)
> 0.399 – – – – 14 1.14
(0.52–2.51)









177:313 OR (all participants): age,
sex, education, parents’
ethnicity, alcohol
drinking, pesticides use≤ 15.4 24 1.0 – – – –
15.5–26.4 44 1.9
(1.1–3.4)
– – – –
>26.4 109 5.3
(3.1–9.0)
– – – –
≤ 20.3 – – 17 1.0 21 1.0 OR (never/ever smokers):
age, sex




[Smokers include current and
former smokers. Non-smokers
with ≤ 20.3 (μg˙•g-1 creatine)













411:566 age, sex, race, smoking
history, education, history
of employment in high
risk occupation, family
history of bladder cancer
< 1 187 1.0 – – – –
1–10 182 0.84
(0.63–1.12)
– – – –
> 10 38 1.10
(0.65–1.86)
– – – –
[Arsenic water concentrations
obtained from: 6,050 private
untreated wells sampled
between 1993–2002; 371 well
water measurements from
participants’ current residence
and; 1,675 measurements from
public well water supplies
collected between 1983–2004,
which were used to estimate
















Table 3 Summary results from case–control studies reporting on arsenic exposure and the risk of bladder cancer (Continued)
*†Steinmaus
et al. 2013 [67]
(Table Two)








306:640 no covariates assessed,
although subjects were
frequency matched on
age, sex0–59 23 1.0 – – – –
60–199 27 0.84
(0.46–1.52)
– – – –
200–799 60 2.50
(1.48–4.22)
– – – –
> 800 122 4.44
(2.75–7.15)
– – – –
[Each city/town of residence in
which each subject lived was
linked to a water arsenic
measurement for that city/
town so that an arsenic
concentration could be
assigned to each year of each
subject’s life. Study also present
OR in relation to various
metrics of arsenic exposure
such as lifetime and cumulative
average exposure and; lifetime
and cumulative intake.
Residential history used in
exposure assessment.]
*Study included in meta-analyses.
†Recent study not included in the International Agency for Research on Cancer 2012 review (Monograph 100C [23]).
1ICD = International Classification of Disease. N/A = not available.
2OR = Odds ratios.






































Morality 1968-83 N/A Group level Median arsenic content
of artesian well and
(range): 0.78 ppm (0.35–




obtained from IARC 2012
review [23].
SMR 871 15 38.8
(21.7–64.0)























of artesian well and
(range): 0.78 ppm (0.35–
1.14); in shallow well: 0.04
(0.00-0.30). Histories of
residential address and
duration of drinking well














SMR 443 age, smoking habits
< 50 254 0.00
(0–12.50)





≥ 1,000 113 31.18
(8.62–91.75)
[Arsenic-polluted area.
Exposure to be between
1955-59. All 34 wells in
the area were sampled
and arsenic concentration
ranged from non detect-















Table 4 Summary results from cohort studies reporting on arsenic exposure and the risk of bladder cancer (Continued)






N/A Group level Cumulative arsenic
exposure derived from:
low exposure (< 1000
ppb-year); medium
(1,000-4,999 ppb-year);
high (≥ 5,000 ppb-year):





records of the Church
of Jesus Christ of Latter-
day Saints (Mormons)
which prohibits tobacco
use and the consump-

















ranging from 14 to 166















from time of enroll-
ment to Dec.1996)






























> 100.0 6 15.3
(1.7–139.9)
[Arsenic levels in shallow
well ranging from < 0.15 to
3,590 μg •˙L−1 and collected
















Table 4 Summary results from cohort studies reporting on arsenic exposure and the risk of bladder cancer (Continued)


























from 0.05 to 25.3 μg˙•L−1,
with mean of 1.2 μg˙•L−1.
Average arsenic
concentrations obtained
from 4,954 samples from
2,487 water utilities
collected, 1987–2004,






































≥ 20.0 20 7.9
(1.7–37.9)
[Period of arsenic water
samples collection not
reported. Participants
used artesian well water
more > 30 years when
recruited. Information
from interview included











































N/A 10–49.9 6 1.85
(0.45–7.61)












< 400 RR 6 1.0




1,000– < 5,000 12 2.44
(0.91–6.50)
5,000– < 10,000 5 3.88
(1.18–12.7)










at time of interview.
Other measures of arsenic
exposure included,













period of 17.8 years)
ICD9 188 SMR based
analyses:
Median arsenic content
of artesian well (range:
700–930 μg˙•L−1)
measured in the early
1960s.
SMRmale 1,563 24 2.9
(27.5–63.8)


















Table 4 Summary results from cohort studies reporting on arsenic exposure and the risk of bladder cancer (Continued)
[Used age-adjusted mor-









HR HR adjusted for age,
gender, education,
smoking habits
< 50 1 1.0
50–710 15 4.35
(0.56–33.52)
> 710 22 7.22
(0.95–55.04)
[Duration of drinking






of well water drinking.]
*Study included in meta-analyses.
†Recent study not included in the International Agency for Research on Cancer 2012 review (Monograph 100C [23]).
1ICD = International Classification of Disease. ICD for cancer site abstracted which included bladder and urothelial/transitional cell carcinoma of the bladder or kidney. Transitional cell carcinoma of the renal pelvis
often share the same etiology as bladder cancer, and as such, have been treated as bladder within the meta-analyses as recommended by IARC [23]. N/A = Not available.
2Cases = number of persons exposed between 1955-1959.
395% Confidence intervals not available for data at low and high exposure.
4Results for transitional cell carcinoma were included in the meta-analysis.
5Results for urothelial carcinoma were included in the meta-analysis.















Table 5 Summary results from ecological studies reporting on arsenic exposure and kidney cancer
Study [reference] (Table
from original publication)
Study locale Outcome Exposure1 [comments] ICD2 Outcome measure Cases Risk estimate
(95% CI)
Chen et al. 19853 [24] (Table
One)
84 villages from 4
neighbouring townships
on SW coast, Taiwan
Mortality 1968-82 Median arsenic content of artesian
well and (range): 780 μg˙•L−1 (350–
1,140); in shallow well: 40 (0.0–300).
Period of samples collection not
reported.
ICD 189 SMRmale 42 7.72 (5.37–10.1)
[Comparison of mortality rate in
Blackfoot disease (BFD) with those of
the general population.]
SMRfemale 62 11.2 (8.38–14.0)




Mortality 1973-86 Arsenic well water concentration
(μg˙•L−1). Period of samples
collection not reported.
ICD 189








[Comparison of mortality rate in BFD
with those of the general
population.]




Mortality 1973-86 Arsenic well water concentration
(μg˙•L−1) based on well water
samples collected between 1964–66.
ICD8 189
< 300 ASMRmale 9 8.42
11 18.9300–590
6 25.3≥ 600
< 300 ASMRfemale 4 3.42
13 19.4300–590
16 58.0≥ 600




Mortality 1972-83 Average arsenic levels in water
















Table 5 Summary results from ecological studies reporting on arsenic exposure and kidney cancer (Continued)
including 4 from BFD
endemic area
units. 73.9% had < 5% of wells with
> 50 μg˙•L−1 ; 14.7% had 5-14%;
11.5% had ≥ 15%. Well water sam-
ples collected between 1974–76.
All precincts & townships ASMRmale – 1.1 (0.2)
ASMRfemale – 1.7 (0.2)
Southwestern townships ASMRmale – 1.2 (0.2)
ASMRfemale – 1.7 (0.3)
Guo et al. 19977 [37] (Table
Two)
243 townships in Taiwan Incidence 1980-87 Arsenic well water concentration
ranging from < 50 to > 640 μg˙•L-1.
ICD 189.0, 189.1 RDmale – 0.03 (0.02)
Estimate presented measured at >
640 μg˙•L-1. [Arsenic measurements
from a National survey of 83,656
wells in 243 townships, collected
mostly between 1974–76.]
RDfemale – 0.14 (0.013)
Rivara et al.1997 [38] (Table
Four)
Chile Mortality 1950-92 Annual average arsenic
concentration in drinking water for
Antofagasta (Region II of Chile)
ranging between 40 to 860 μg˙•L-1.
Data from historical records from
1950–1992.
ICD 189 RR – 3.8 (3.1–4.7)
[Comparison of mortality rate in
Region II (exposed) populations vs
Region VIII (control population.]
Smith et al. 1998 [39] Chile Mortality 1989-93 Region II of Northern Chile with
population weighted average arsenic
concentration in drinking water up
to 569 μg˙•L−1 compared with the
rest of Chile; exposure generally < 10
μg˙•L−1.
N/A SMRmale 39 1.6 (1.1–2.1)
[Arsenic measurements from 1950–
94.]
SMRfemale 34 2.7 (1.9–3.8)
Hinwood et al. 1999 [88]
(Table Two)
22 areas in Victoria,
Australia
Incidence 1982-91 Median water arsenic concentration
ranging 13 μg˙•L−1 to 1,077 μg˙•L−1.
[Selected areas were those where
samples with soil and/or water
arsenic concentration were generally
in excess of 10 μg˙•L-1. Period for
samples collection is not available.]
ICD 189.0, 189.9 SIR 134 1.16 (0.98–1.37)
*Tsai et al. 1999 [41] (Tables
Two, Three)
4 townships from BFD
endemic area in SW
coast, Taiwan
Mortality 1971-94 Median arsenic content of artesian
well: 780 μg˙•L−1 (range: 350–1,140).
ICD 189 SMRlocal-male 94 6.76 (5.46–8.27)
SMRnational-male 94 6.80 (5.49–8.32)
Period of samples collection not
reported. Authors state that artesian















Table 5 Summary results from ecological studies reporting on arsenic exposure and kidney cancer (Continued)
wells were no longer used by the
mid-1970s.
[Comparison of mortality in BFD
endemic area with that of a local
reference population (Chiayi-Tainan
county) and that of Taiwan as a
whole.]
SMRnational-female 128 10.5 (8.75–12.5)




Mortality 1979-97 Population weighted median arsenic
concentration in water of 7.58 μg˙•L−1,
with a range between 10–100 μg˙•L−1.
Data from 9,251 well water samples
collected between 1983–2002.
ICD9 189 SMRmale 325 1.06 (0.91–1.22)
SMRfemale 194 1.00 (0.82–1.20)
†Yuan et al. 2010 [61] (Tables
Two, Three)
Region II and V, Chile Mortality 1950-2000 Northern Chile (Region II) with
population weighted average arsenic
concentration in drinking water up
to 569 μg˙•L-1 vs Region V with
exposure close to 1 μg˙•L-1.
Between 1958-70, arsenic concentra-
tion in water supply of Antofagasta
and nearby Mejillones (Region II) av-
eraged 870 μg˙•L-1 and declined in






RRmale-1950–54 4 0.69 (0.23–2.02)
RRmale-1955–59 9 1.43 (0.66–3.10)
RRmale-1960–64 7 0.91 (0.40–2.08)
RRmale-1965–69 12 2.51 (1.22–5.17)
RRmale1970–74 15 1.45 (0.81–2.60)
RRmale1975–80 19 2.13 (1.24–3.68)
RRmale1981–85 39 3.37 (2.21–5.11)
RRmale1986–90 63 2.81 (2.05–3.85)
RRmale1991–95 50 1.78 (1.28–2.47)
RRmale1996–00 66 1.61 (1.21–2.14)
RRfemale-1950–54 2 1.27 (0.27–6.00)
RRfemale-1955–59 2 0.30 (0.07–1.25)
RRfemale-1960–64 7 1.66 (0.71–3.91)
RRfemale-1965–69 3 0.76 (0.23–2.57)
RRfemale1970–74 13 3.70 (1.81–7.56)
RRfemale1975–80 9 1.71 (0.80–3.65)
RRfemale1981–85 25 2.89 (1.77–4.72)
RRfemale1986–90 41 3.23 (2.18–4.78)
RRfemale1991–95 49 4.37 (2.98–6.41)
RRfemale1996–00 47 2.32 (1.64–3.28)
Young adults aged 30-39 years, born
during and just before high-exposure
period; and for ages 40+, born before















Table 5 Summary results from ecological studies reporting on arsenic exposure and kidney cancer (Continued)
SMRmale_30-49 years 4 5.63 (1.52–14.4)
SMRmale_40 years+ 103 2.68 (2.19–3.26)
SMRfemale_30-49 years 4 9.52 (2.56–24.4)
SMRfemale_40 years+ 84 3.91 (3.12–4.84)
SMRtotal_30-49 years 8 7.08 (3.05–14.0)
SMRtotal_40 years+ 187 3.12 (2.69–3.61)
*Study included in meta-analyses.
†Recent study not included in the International Agency for Research on Cancer 2012 review (Monograph 100C [23]).
1All ecological studies assessed arsenic exposure at the group-level.
2ICD = International Classification of Disease. N/A = not available.
3SMR, standardized mortality ratio.
4Age-standardized mortality rates per 100,000 using the 1976 world population as standard population and based on 899,811 person-years.
5All age-standardardized mortality rates shown are significant at p < 0.001 based on trend test.
6Regression coefficient showing an increase in age-adjusted mortality per 100,000 persons-years for every 0.1 ppm increase in arsenic level, adjusting for indices of industrialization and urbanization. Standard errors
are in brackets. Kidney cancer was significantly correlated with average arsenic level in water.






































Morality 1968-83 N/A Group level Median arsenic content of artesian
well and (range): 0.78 ppm (0.35–
1.14); in shallow well: 0.04 (0.00-0.30).
General population used as
reference. 95% CI obtained from
IARC 2012 review [23].
SMR 871 3 19.5
(4.0–57.0)







N/A Group level Cumulative arsenic exposure derived
from: low exposure (< 1000 ppb-
year); medium (1,000-4,999 ppb-
year); high (≥ 5,000 ppb-year):
SMRmale 4,058 – 1.75
(0.80–3.32)
Individual data on cofactors not
available. However, the cohort
was assembled from historical
membership records of the
Church of Jesus Christ of Latter-
day Saints (Mormons) which pro-
hibits tobacco use and the con-
sumption of alcohol and caffeine.
SMRfemale – 1.60
(0.44–4.11)
< 1,000 ppb•year SMRmale – 2.5
SMRfemale – 2.4
1,000 - 4,999 ppb•year SMRmale – 1.1
SMRfemale – 1.3
≥ 5,000 ppb•year
[Residential history combined with
local water records used to assess
exposure. High variability in exposure
estimates in each community with
median arsenic concentrations
ranging from 14 to 166 ppb. Records






























[Average arsenic exposure from 0.05
to 25.3 μg˙•L−1, with mean of 1.2
μg˙•L−1. Average arsenic
concentrations obtained from 4,954
samples from 2,487 water utilities
collected, 1987–2004, with most
samples dating 2002–04. Residential
history 1970–2003.]
†Recent study not included in the International Agency for Research on Cancer 2012 review (Monograph 100C [23]).
1ICD = International Classification of Disease. N/A = not available.















17 studies included in meta-analysis
241 References identified from 
PubMed
50 studies retrieved for 
full text review
199 abstracts excluded for 
being reviews, or non-




9 studies excluded due to wrong 
exposure (e.g. arsenic 
from smelters, plants etc.)
1 study with previously published 
results excluded
4 studies identified from 
Google Scholar
4 studies identified from 
hand search
249 references identified 
and abstract reviewed























































Figure 1 Study selection process. Note that several studies report on more than one cancer site.
Saint-Jacques et al. Environmental Health 2014, 13:44 Page 24 of 32
http://www.ehjournal.net/content/13/1/44water (well or tap water), whereas all case–control and
most cohort studies (7 of 9 studies) assessed As exposure
using either a direct measure of As in tap/well water or
body burden (e.g. urine or toenail As concentrations) oran individual level measure estimated from a range of
metrics, including the reconstruction of past exposures
based on residential history, knowledge of water source
and duration of exposure to As contaminated well
Figure 2 Arsenic concentrations from studies reporting on urinary tract cancers outcomes and arsenic exposure in drinking water.
† indicates studies reporting significant associations and square brackets indicates citation number. Studies included in the meta-analysis are
shown with an asterisk (*). Of the 40 studies reviewed, 3 used biomarkers to measure As exposure [51,94,95] and 2 failed to provide a specific
measure of As-concentration [28,37].
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http://www.ehjournal.net/content/13/1/44drinking water (see Table 2, 3, 4, 5, 6, As exposure assess-
ment). Fifteen ecological studies and one cohort study
stratified the analysis by gender (Tables 2, 4, 5, 6). With
the exception of one study [70], all case–control and co-
hort studies included in this review accounted for tobacco
smoking and one ecological study used lung cancer
mortality rates as surrogate to smoking [63].
Arsenic exposure and bladder cancer
Ecological studies
Fifteen of the 20 ecological studies reviewed reported on
bladder cancer mortality (Table 2). These studies pro-
vided consistent evidence for an increased risk of death
from bladder cancer with exposure to As in drinking
water. There were two exceptions, however, they focused
only upon low exposures (< 60 μg/L As in water; [89,90]).
Risk estimates amongst males and females were compar-
able, with the exception of those reported by Chen et al.
[24] which showed a near doubling of risk in females on
the southwest coast of Taiwan (Table 2). Chen [26] was
also first to describe a dose–response relationship between
well water As and rates of mortality from bladder cancer.
In accordance with the three levels of As exposure exam-
ined (< 300; 300 – 590; > 600 μg/L As), age-adjustedcancer mortality rates per 100,000 were as follows: 15.7,
37.8, 89.1 per 100, 000 males and 16.7, 35.1, 91.5 per
100,000 females. While these findings profiled the highly
exposed populations of Taiwan, increased mortality from
bladder cancer due to As exposure in drinking water was
also observed in Argentina [35,36,62,63] and Chile
[38,39,55]. For example, compared to un-contaminated
areas, males and females from the highly contaminated Re-
gion II of Chile, experienced mortality rates due to bladder
cancer, 6.0 and 8.2 times greater, respectively [39]. Within
the same region, Rivara et al. [38] reported on mortality
rates of an order of magnitude higher (sex combined) rela-
tive to those observed in the rest of Chile. Findings from
the 4 ecological studies reporting on bladder cancer inci-
dence were generally consistent with those of studies based
on mortality, providing evidence for an association between
bladder cancer and exposure to As in drinking water. The
exception was a study by Hinwood et al. [88] which was
limited by low power and exposure misclassification.
Case–control studies
Ten of the 11 case–control studies reviewed reported
on bladder cancer incidence [20,31,51,67,87,91-95]; one re-
ported on mortality ([25]; Table 3). Four studies observed a
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one study observed an increased risk of death with increas-
ing years of artesian well water consumption in Blackfoot
disease endemic areas of Taiwan ([25]; Table 3). Two of
these studies assessed As exposure from As in tap/well
water, one from urine, one from cumulated exposure and
one from years of artesian well water consumption. Three
of the five studies reporting a significant association, also
provided risk estimates by smoking status [20,31,51]. Two
studies failed to find an effect among non-smokers [20,31];
one study reported a risk of about half the magnitude of
that observed among smokers (never smokers: 4.4 [2.3 –
8.5] vs smokers: 8.2 [3.8 – 17.8]; Table 3) [51]. Regardless
of the type of metric used to measure exposure
(i.e. cumulative dose index, As in drinking water, body bur-
den etc.), the risk of developing bladder cancer as a result
of exposure to As, was consistently higher among smokers.
Cohort studies
Five of the 9 cohort studies reviewed reported on bladder
cancer incidence [32,33,53,60,96]; four reported on mortal-
ity (34,40,65,70]; Table 4). Seven of the 9 cohort studies
showed an association between exposure to As contami-
nated drinking water and either bladder cancer incidence
(4 studies, [32,33,53,60]) or mortality (3 studies, [34,65,70]).
The work of both Chiou et al. [33] and Chen et al. [60] pro-
vided significant evidence for a dose–response relationship
over a broad range of As exposure, from < 10 μg/L to ≥
300 μg/L. Chen et al. [60] report relative risk estimates for
bladder cancer increasing from 1.9, 2.2, 5.5 and 10.8 for ex-
posure to As ranging from < 10, 10 – 49.9, 50 – 99.9, 100 –
299.9 and ≥ 300 μg/L, respectively. Consistent with these
findings, Chiou et al. [33] report risks of similar magnitude,
increasing from 1.9, 8.2, and 15.3 for exposure to As ran-
ging from 10 – 50 μg/L, 50.1 – 100 μg/L and > 100 μg/L,
respectively. The largest cohort study involving 56,378 cases
failed to provide evidence of an association [96]. However,
average exposure ranged of 0.05 and 25.3 μg/L and mean
exposure level was 1.2 μg/L, with the authors indicating
that only a small proportion of subjects were exposed to
drinking-water containing As at > 2 μg/L. Eight of the 9
cohort studies retained in this review adjusted for the effect
of tobacco smoking [32-34,40,53,60,65,96].
As exposure and kidney cancer
Ecological studies
Nine of the 20 ecological studies reviewed reported on
kidney cancer mortality (Table 5). Eight of these studies
provided evidence for an increased risk of death from
kidney cancer with exposure to As in drinking water
[24,26-28,38,39,41,61]; one study found no association
[90]. At high levels of As exposure risk estimates were
generally higher amongst females. Chen [26] was again,
first to describe a dose–response relationship between wellwater As and rates of mortality from kidney cancer,
reporting age-standardized rates increasing from: 5.4, 13.1,
21.6 per 100, 000 males and 3.6, 12.5, 33.3 per 100,000 fe-
males, with exposure to < 300, 300 – 590, and > 600 μg/L
As, respectively (Table 5). Two ecological studies reported
on kidney cancer incidence [37,88] and one of these pro-
vided evidence for an association between kidney cancer
and exposure to As in drinking water [37].
Case–control studies
None of the 11 case–control studies identified in this
review reported on kidney cancer.
Cohort studies
One of the 9 cohort studies reported on kidney cancer
incidence [96]; two reported on mortality [40,70] (Table 6).
Of these 3 studies, one study showed a statistically signifi-
cant increase in mortality with exposure to As contami-
nated drinking water [70]; the others reported a non
significant increased risk in mortality [40] or incidence
[96]. None of the cohort studies reviewed provided
evidence for a dose–response relationship. Overall, as
observed with ecological studies, the magnitude of the
published risk estimates for kidney cancer was consist-
ently lower than that observed for bladder or urinary
organs cancer outcomes.
Meta-analyses, Model I
Analyses based on combined epidemiologic data showed
an increase in the risk of developing bladder cancer or
dying from bladder or kidney cancers with exposure to
increasing levels of As in drinking water (Figure 3A-C).
Combined bladder cancer SMRs ranged from < 1.0 (As
concentration mid-point < 10 μg/L) to 38.8 (As concen-
tration mid-point of 780 μg/L; Figure 3A), showing a
significant increase in risk at higher levels of exposure
(R2 = 0.96, p < 0.0001). Similarly, cancer mortality rates
also significantly increased with increased well-water As
(Figure 3B; R2 = 0.92, p < 0.001). However, the magni-
tude of the association was three times greater in those
dying from bladder cancer relative to those dying from
kidney cancer (p < 0.0001). Bladder cancer mortality rates
ranged from 15.7 (As mid-point of 150 μg/L) to 91.5 per
100,000 persons (As mid-point of 870 μg/L); kidney cancer
mortality rates ranged from 5.4 (As mid-point of 150 μg/L)
to 58.0 per 100,000 persons (As mid-point of 870 μg/L).
Combined RRs for bladder cancer incidence studies, ranged
from 1.0 (As mid-point of 5 μg/L) to 15.3 (As mid-point of
1,845 μg/L) and also indicated a statistically significant
increase in risk with increasing well-water As (Figure 3C;
R2 = 0.87, p < 0.0001). Predicted incidence risk of for
bladder cancer increased 2.7 [1.2 – 4.1]; 4.2 [2.1 – 6.3]
and; 5.8 [2.9 – 8.7], in those drinking water contaminated
with 10 μg/L; 50 μg/L and; 150 μg/L of As, respectively.
Figure 3 Published risk estimates for varying levels of arsenic
in drinking water in relation to bladder and kidney cancer
mortality (A-B) and bladder cancer incidence (C). Solid lines
show the predicted risk from the model fitted values obtained from
meta-analyses; referent study for analyses is in bold; R2 is the
coefficient of determination based upon best fit to distributional
assumption. RRs were all adjusted for tobacco smoking. Citation for
original publication is in square brackets.
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The robustness of the effect size at 10, 50 and 150 μg/L of
As in drinking water for all three reported outcomes (mor-
tality rates, SMR, RR) was assessed with Model II. The pre-
dicted risk derived from the bootstrapped randomizations
(Figure 4A-D) confirms the non-linear increase in bothbladder and kidney cancer mortality and in bladder cancer
incidence with increasing levels of As in drinking water
which was observed with Model I. However, the magnitude
of the effect size for bladder cancer incidence (Figure 4D)
was about 50% lower than those of Model I for exposure
to 10, 50 and 150 μg/L of As in drinking water: 1.4, 2.3 and
3.1(Model II) versus 2.7, 4.2 and 5.8 (Model I; Figure 4D).
For bladder cancer mortality, the median SMR increased
from 1.0 to 1.7 and 2.2 at 10, 50 and 150 μg/L, respectively.
For both bladder and kidney cancers, mortality rates at
150 μg/L was about 30% greater than those recorded at
10 μg/L (Figure 4A-C). Although, these effect sizes were
not statistically significant, they did follow a dose–
response relationship across all outcome measures. In
addition, 51% and 65% of the probability density distri-
bution in predicted SMRs and RRs, respectively, fells
above 1.0 (no risk) at the lowest exposure benchmark of
10 μg/L, with these proportions increasing to 74% and
83% for SMR and RR at levels of 50 μg/L.
Discussion
Summary of findings
This review evaluated 40 studies reporting on the associ-
ation between As in drinking water and urinary tract
cancers. Evidence supporting an increased risk of develop-
ing, or dying from, bladder cancer as a result of exposure
to As in drinking water was obtained from 28 studies from
Taiwan, Chile, Argentina, Japan and Finland. Furthermore,
evidence supporting an increased risk of developing, or
dying from, kidney cancer due to As in drinking water
was obtained from 10 studies from Taiwan and Chile. The
risk associated with kidney cancer was consistently of
lower magnitude than that reported for bladder cancer
outcomes.
Twenty of the 40 studies reviewed were ecological by
design, not accounting for potential confounders and
with As exposure assigned using well water concentra-
tion from geographic or other grouped measurements,
which could have resulted in the misclassification of
exposure. However, the majority of these studies focused
on highly exposed populations where the magnitude of
the effects reported was so high that potential confound-
ing or misclassification bias could not fully explain the
associations.
Tabulated risk estimates from studies assessing exposure
from As in well/tap drinking water, were generally mea-
sured within a limited range of As concentrations and var-
ied across, and within regions, even in areas where similar
concentrations of As had been measured. Differences in
exposure (e.g. As species, timing and duration of exposure)
[52] and population characteristics (e.g. genetic variations,
lifestyle habits–smoking, diet etc.) have been suggested to
contribute to differences in inter-individual susceptibility
[52,102,103]. Thus, the methodological limitations of the
Figure 4 Distribution of predicted cancer risk estimates (A-B: mortality rates for bladder and kidney cancers; C: standardized mortality
ratio for bladder cancer; D: incident relative risk for bladder cancer) at three levels of arsenic concentrations (10, 50 and 150 μg/L) in
drinking water. Distributions were obtained from a bootstrap randomization of the fixed effects arsenic-risk models which were parameterized
as a function of logged arsenic and the study from which the data were derived. A total of 10,000 randomizations were used.
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(e.g. level of exposure assessment, lack of adjustment for
potential confounders or effect modifiers such as age, sex,
cigarette smoking, may have influenced the magnitude of
the associations reported. For example, some case–control
studies reporting on low exposure levels noted a significant
association only among smokers [20,31] and of the cohort
studies carried out in Taiwan, those adjusting for such co-
variates [33,53,60] reported risk estimates three to fourfold
lower than ecological studies that did not [24,26].
Meta-analysis of arsenic in drinking water and the risk of
developing bladder or kidney cancers
The analyses of combined risk estimates presented in
this review allowed for the examination of the associ-
ation between cancer outcomes (i.e. mortality and inci-
dence) – independently, and As exposure over a broader
and more continuous range of As concentrations. After
adjusting for differences in unaccounted bias associated
with each study, the results showed that exposure to in-
creasing levels of As in drinking water was significantly
associated with an increased risk of bladder and kidney
cancer mortality and bladder cancer incidence, regardless
of the measure of association employed (i.e. mortality rate,
SMR, RR; Model I). Risk estimates obtained from fitted
values from Model I showed that people exposed to drink-
ing water contaminated with 10 μg/L of As had more than
a twofold increased risk of developing bladder cancer (2.7
[1.2 – 4.1]); those exposed to 50 μg/L and 150 μg/L were
expected of have a four- (4.2 [2.1 – 6.3]) and six fold (5.8
[2.9 – 8.7) increase in risk, respectively– relative to themeta-analyses referent group (the general population of
Taiwan). Sub-analyses focusing on low-level exposure (≤
150 μg/L) confirmed the trend, although the effect was
slightly reduced at the 150 μg/L exposure level (10 μg/L,
RR: 2.8 [1.3 – 4.3]; 50 μg/L, RR: 3.7 [1.7 – 5.7]; 150 μg/L,
RR: 4.5 [1.8 – 7.2]). A near six fold increase in bladder
cancer risk was also observed by Chen et al. [60] in north-
eastern Taiwanese residents exposed to levels of As in
drinking water ranging between 100–299.9 μg/L (RR: 5.5
[1.4 – 22.0]). However, predicted risks for people exposed
to 10 and 50 μg/L were about half of those obtained with
Model I but comparable to those of Model II (Figure 4D;
see also Chiou et al. [33] for a doubling of risk between
50-100 μg/L). Of note, a recent review reporting on low-
level As exposure in drinking water and bladder cancer
did not support a significant association [56]. However,
their findings were based on a meta-analytical approach
that combined incidence and mortality outcomes, and
studies using different metrics of exposure (e.g. As in toe-
nails, well water, cumulated etc.), which possibly intro-
duced statistical noise thereby attenuating the summary
estimate (risk) towards the null. In this review, risk
estimates derived from mortality were smaller than those
of incidence data (Figure 4C-D). This possibly reflected
patterns of prognosis [104], but perhaps more so, re-
duced statistical power due to misclassification as eight
of the nine studies included in the meta-analyses of
SMRs assessed exposure at the group-level, whereas all
studies included in the analyses of the incidence data
used individual-level measurements or estimations of
As in drinking water.
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with drinking water containing As has been difficult to
establish, especially in populations exposed to moderate
to low As-levels. A major issue relates to the misclassifi-
cation of As exposure arising from uncertainties in
assessing exposures during the disease-relevant exposure
period, which, for As, may extend many decades prior to
diagnosis. These uncertainties relate to population mo-
bility, characterization of drinking water sources, assign-
ment of water As concentrations to subjects over time,
assessment of fluid intake rates, assessment of dietary As
intake, a likely major contributor to exposure in areas of
low As-levels [103,105], and difficulties in measuring
actual levels of As in drinking water as opposed to rely-
ing on estimated levels [56]. Such uncertainties lead to
bias which typically results in an underestimation of the
true risk— a risk that can be small but still biologically
significant.
These uncertainties also act to increase the variability
in the distribution of both the measured (e.g. Figure 3)
and consequently, the predicted (e.g. Figure 4) risks, weak-
ening the statistical significance of the risk estimate. Stud-
ies using biomarkers of exposure offer perhaps a way to
reduce such uncertainties that create exposure misclassifi-
cation. However, rather than limiting the dialogue around
As-related health effects to a significance level, perhaps
more informative is the high probability that a large pro-
portion of people may be at elevated risk of dying from
(Figure 4C, 51% probability) or being diagnosed with blad-
der cancer (Figure 4D, 65% probability), even at exposure
levels as low as 10 μg/L. In this review, we estimate that
with exposure to 50 μg/L of As in drinking water there is
a 83% probability for an elevated risk of developing blad-
der cancer and a 74% probability of elevated mortality.
(Figures 4C, 4D). Yet, hundreds of millions of people
worldwide rely upon drinking water containing As at these
concentrations and consider them to be safe [3,69].
Limitations and strengths
This review has some limitations. First, the search strategy
was limited to computerized databases which could pref-
erentially include studies with statistically significant find-
ings [106,107]. While this is a concern, we are confident
that publication bias was possibly minimal as a third of
the studies included in this review presented non-
significant results. Second, the analyses of combined risk
estimates were limited to studies providing specific point
estimates of As in drinking water, the most common
metric of exposure reported. This selection reduced the
number of studies eligible for meta-analyses but mini-
mized heterogeneity associated with other exposure
metrics such as cumulative As exposure or As concen-
trations in toenails or urine; two measures linked to
population/individual-dependent factors (e.g. years ofexposure, cumulated volume of contaminated water
ingested, metabolic capacity etc.). Third, analyses were
performed independently for studies reporting on differ-
ent outcomes (i.e. cancer incidence vs. cancer mortality)
and different measures of association (i.e. mortality rate,
SMR, RR). This stratified approach reduced the statis-
tical power required to analyze the combined data by
sex and/or smoking status; the latter being an important
effect modifier in the cancer-As relationship. Studies
supporting a higher risk among ever smoker are grow-
ing in number and so predicted risks presented in this
review may be conservative for populations with a high
proportion of ever smokers.
Nonetheless, this review has important strengths. First,
its broad scope allowed for the inclusion of 30 years of
publications and a wide range of exposure from which
combined analyses could be performed. Second, the use
of a sensitive search strategy ensured a high level of
search completeness. Third, while the independent ana-
lyses of incidence and mortality outcomes was presented
as a limitation in terms of statistical power, it likely min-
imized possible ascertainment bias and exposure mis-
classification issues. This is because mortality data are
generally less precise than incidence data and the survival
rate for bladder cancer is relatively high. In addition, if
survival for bladder cancer patients is related to As expos-
ure, then mortality studies could be at greater risk of being
confounded compared to incidence studies [104]. Further-
more, exposure in mortality studies is often derived from
aggregate data which are more prone to misclassification
and bias. Finally, this review updates and complements
previously published work, but also provides data which
quantifies the risk of developing bladder cancer at varying
levels of As exposure, including that observed at lower
levels exposure.
Conclusions
Epidemiological studies provide extensive evidence in sup-
port of a causal association between exposure to higher
levels of As concentrations in drinking water and the risk
of developing or dying from bladder cancer, although the
thresholds at which health effects develop remain uncer-
tain at lower levels of As exposure in drinking water. Evi-
dence in support of an increased risk of dying from kidney
cancer with exposure to As is also accumulating, but stud-
ies reporting on incidence are lacking.
The results of the meta-analysis were consistent with
the generally observed findings from the full body of
literature reporting on bladder and kidney cancer out-
comes and As-exposure. They also confirmed patterns
of dose-responses within exposed populations and quan-
tified the evidence for potential health effects at the
lower end of the exposure curve where most uncertain-
ties remain. This meta-analysis suggests that populations
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increasing their risk of dying from bladder or kidney
cancer by 30% relative to those exposed to 10 μg/L. In
addition, populations exposed to As concentrations as
low as 10 μg/L in drinking water, (which corresponds to
the WHO provisional guideline), may be doubling their
risk of developing bladder cancer, or at the very least,
increase it by about 40% compared to the unexposed
populations included in the meta-analyses.
Thus, with the large number of people likely exposed
to As in drinking water at the lower range of concentra-
tions throughout the world, we suggest that the public
health consequences of As in drinking water may be
substantial. And as such, the current advisory limit for
concentration of As in drinking water should be reviewed
as well as policies on the promotion and support of house-
hold water arsenic remediation activities. Further studies
focusing on populations exposed to low As concentrations
with exposure measured at the individual level (e.g. bio-
marker studies), are required to confirm the observed
health effect suggested in this review.
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